Abstract
Bleomycin is a polypeptide antibiotic, anti-neoplastic agent, which has been used in the treatment of germ cell tumours for over 20 years. Pulmonary toxicity has been known since the early clinical trials in the 1960’s.There are a surprisingly few large studies examining risk factors for bleomycin lung toxicity in germ cell cancers. Suggested risk factors include cumulative dose, reduced renal (EDTA) clearance, raised creatinine, age of patient, and major surgery.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag London Limited
About this paper
Cite this paper
O’Sullivan, J.M., Norman, A.R., Nicholls, J., Huddart, R.A., Dearnaley, D.P., Horwich, A. (2002). Factors Associated with Bleomycin Lung Toxicity in Germ Cell Tumour Patients Treated at the Royal Marsden Hospital Between 1982 and 1999. In: Harnden, P., Joffe, J.K., Jones, W.G. (eds) Germ Cell Tumours V. Springer, London. https://doi.org/10.1007/978-1-4471-3281-3_48
Download citation
DOI: https://doi.org/10.1007/978-1-4471-3281-3_48
Publisher Name: Springer, London
Print ISBN: 978-1-4471-3283-7
Online ISBN: 978-1-4471-3281-3
eBook Packages: Springer Book Archive